Rocket


Overview
Financials
News + Filings
Key Docs
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Tango Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 144 Form 144 - Report of proposed sale of securities:
10/10/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 D Form D - Notice of Exempt Offering of Securities:
08/21/2023 SC 13G Nextech Crossover I GP S.a r.l. reports a 5.4% stake in Tango Therapeutics, Inc.
08/16/2023 SC 13D/A BCTG Holdings, LLC reports a 13.9% stake in Tango Therapeutics, Inc.
08/10/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "Form of Pre-Funded Warrant",
"Securities Purchase Agreement, by and among Tango Therapeutics, Inc. and the parties named therein",
"Tango Therapeutics Announces $80 million Private Placement Financing"
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Consolidated Statements of Operations Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Collaboration revenue 9,598 5,771 15,364 11,529 License revenue 5,000 — 5,000 — Total revenue 14,598 5,771 20,364 11,529 Operating expenses: Research and development 28,671 23,741 56,710 48,071 General and administrative 9,174 7,232 17,188 14,039 Total operating expenses 37,845 30,973 73,898 62,110 Loss from operations Other income, net 2,601 347 4,880 518 Provision for income taxes Net loss $ $ $ $ Net loss per common share – basic and diluted $ $ $ $ Weighted average number of common shares outstanding – basic and diluted 88,354,590 87,839,804 88,281,368 87,775,440 Condensed Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equ..."
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Consolidated Statements of Operations Three Months Ended March 31, 2023 2022 Total revenue 5,766 5,758 Operating expenses: Research and development 28,039 24,330 General and administrative 8,013 6,807 Total operating expenses 36,052 31,137 Loss from operations Other income, net 2,278 171 Net loss $ $ Net loss per common share – basic and diluted $ $ Weighted average number of common shares outstanding – basic and diluted 88,193,917 87,670,653 Condensed Consolidated Balance Sheets March 31, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 57,252 $ 59,968 Marketable securities 276,387 306,165 Accounts receivable — 2,000 Restricted cash — 567 Prepaid expenses and other current assets 9,361 6,572 Total current assets 343,000 375,272 Property and equipment, net 11,106 ..."
04/24/2023 ARS Form ARS - Annual Report to Security Holders:
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Quarterly results
Docs: "Consolidated Statements of Operations Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Total revenue 6,411 5,716 24,860 37,042 Operating expenses: Research and development 29,091 21,634 105,906 77,636 General and administrative 7,887 6,066 30,025 17,596 Total operating expenses 36,978 27,700 135,931 95,232 Loss from operations Other income, net 1,558 115 2,949 247 Loss before income taxes Provision for income taxes Net loss $ $ $ $ Net loss per common share – basic and diluted $ $ $ $ Weighted average number of common shares outstanding – basic and diluted 87,971,485 87,567,676 87,820,037 62,108,032 Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 59,968 $ 142,745 Marketable securities 306,165 342,510 Acc..."
02/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development"
02/14/2023 SC 13G/A Cormorant Asset Management, LP reports a 4.7% stake in Tango Therapeutics, Inc.
02/09/2023 SC 13G/A FMR LLC reports a 8.3% stake in TANGO THERAPEUTICS INC
02/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
09/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/21/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
09/13/2022 EFFECT Form EFFECT - Notice of Effectiveness:
09/01/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/10/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/10/2022 8-K Quarterly results
07/11/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
06/10/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/10/2022 8-K Quarterly results
05/11/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
04/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy